Title
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1<inf>19</inf>) and T helper epitopes of tetanus toxoid
Date Issued
14 October 1999
Access level
metadata only access
Resource Type
journal article
Author(s)
Keitel W.A.
Kester K.E.
Atmar R.L.
Bond N.H.
Holland C.A.
Krzych U.
Palmer D.R.
Egan A.
Diggs C.
Ballou W.R.
Hall B.F.
Kaslow D.
Baylor College of Medicine
Publisher(s)
Elsevier
Abstract
The safety and immunogenicity of 2 yeast-derived, blood-stage malaria vaccines were evaluated in a phase l trial. Healthy adults were given 2 or 3 doses of alum-adsorbed vaccine containing the 19 kDa carboxy-terminal fragment of the merozoite surface protein-1 (MSP-119) derived from the 3D7 or the FVO strain of Plasmodium falciparum fused to tetanus toxoid T-helper epitopes P30 and P2. The first 2 doses of MSP-119 were well tolerated. Hypersensitivity reactions occurred in 3 subjects after the third dose of MSP-119, including bilateral injection site reactions in 2 (one with generalized skin rash), and probable histamine-associated hypotension in 1. Serum antibody responses to MSP-119 occurred in 5/16, 9/16 and 0/8 subjects given 20 μg of MSP-119, 200 μg of MSP-119, and control vaccines (hepatitis B or Td), respectively. Both MSP-119 vaccines were immunogenic in humans, but changes in formulation will be necessary to improve safety and immunogenicity profiles. Copyright (C) 1999 Elsevier Science Ltd.
Start page
531
End page
539
Volume
18
Issue
June 5
Language
English
OCDE Knowledge area
Inmunología
Subjects
Scopus EID
2-s2.0-0032866084
PubMed ID
Source
Vaccine
ISSN of the container
0264410X
Sponsor(s)
This research was supported by in part by contracts NO1-AI-25135, from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health; the United States Agency for International Development through interagency agreements with the Walter Reed Army Institute of Research and NIAID. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Department of the Army or the Department of Defense.
Sources of information:
Directorio de Producción Científica
Scopus